Amedisys (AMED) Stock Forecast & Price Target

$97.17

+0.02 (+0.02%)

(As of 09/6/2024 ET)

Amedisys - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 5 Analyst Ratings

Based on 5 Wall Street analysts who have issued ratings for Amedisys in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 4 have given a hold rating, and 1 has given a buy rating for AMED.

Consensus Price Target

$100.67
3.60% Upside

High Forecast	$101.00
Average Forecast	$100.67
Low Forecast	$100.00

According to the 5 analysts' twelve-month price targets for Amedisys, the average price target is $100.67. The highest price target for AMED is $101.00, while the lowest price target for AMED is $100.00. The average price target represents a forecasted upside of 3.60% from the current price of $97.17.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	10 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$100.67	$100.67	$100.80	$109.60
Forecasted Upside	3.60% Upside	4.72% Upside	10.48% Upside	23.95% Upside

Get Amedisys Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

War on Elon Escalates…

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

AMED Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AMED Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amedisys Stock vs. The Competition

Type	Amedisys	Medical Companies	S&P 500
Consensus Rating Score	2.20	2.77	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	3.60% Upside	1,207.55% Upside	11.35% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/29/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Downgrade	Buy ➝ Hold	$101.00 ➝ $101.00	+2.80%
7/25/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$101.00 ➝ $101.00	+3.06%
7/1/2024	William Blair 2 of 5 stars	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform
3/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$97.00 ➝ $100.00	+8.52%
7/31/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$84.00 ➝ $101.00	+11.22%
Get the Latest News and Ratings for AMED and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.
7/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/27/2023	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/27/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$97.00 ➝ $101.00	+10.99%
6/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$88.00 ➝ $101.00	+10.99%
6/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral
5/5/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$96.00 ➝ $81.00	+1.30%
3/14/2023	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Equal Weight	$103.00	+30.43%
1/19/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $125.00	+34.12%
1/5/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Market Perform	$96.00 ➝ $85.00	-1.16%
11/4/2022	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$88.00	+1.77%
11/4/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$103.00	+19.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:05 PM ET.

AMED Forecast - Frequently Asked Questions

What is Amedisys' forecast for 2024?: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Amedisys is $100.67, with a high forecast of $101.00 and a low forecast of $100.00.
Should I buy or sell Amedisys stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
Does Amedisys's stock price have much upside?: According to analysts, Amedisys's stock has a predicted upside of 4.72% based on their 12-month stock forecasts.
Has Amedisys been downgraded by Wall Street analysts recently?: Over the previous 90 days, Amedisys's stock had 2 downgrades by analysts.
What analysts cover Amedisys?: Amedisys has been rated by research analysts at Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, and William Blair in the past 90 days.
Do Wall Street analysts like Amedisys more than its competitors?: Analysts like Amedisys less than other "medical" companies. The consensus rating for Amedisys is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AMED compares to other companies.